Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, with Chronic Hepatitis C Infection

Journal of Pediatric Gastroenterology and Nutrition

Volumn 66, Issue 3, 2018, Pages 425-427

  El Shabrawi, Mortada H ^a   Abdo, Alaa M ^b   El Khayat, Hisham R ^c   Yakoot, Mostafa ^d  

^a CAIRO UNIVERSITY   (Egypt)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

^d Green CRC   (Egypt)

Author keywords

adolescents; chronic hepatitis C; daclatasvir; response tailored therapy; sofosbuvir; sustained vRVR at week 12 post treatment; very rapid virologic response

Indexed keywords

DACLATASVIR; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; FOLLOW UP; HEPATITIS C VIRUS; HUMAN; MALE; NAUSEA; PILOT STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; CHILD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 85042430934     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000001838     Document Type: Article

References (9)

1. FDA News Release. FDA approves two hepatitis C drugs for pediatric patients. FDA Web site. https://www.fda.gov/newsevents/newsroom/ pressannouncements/ucm551407.htm. Accessed August 2, 2017.
2. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 2017;66:153-94.
3. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370:1879-88.
4. Curry M, Modi AA, Pungpapong S, et al. Realworld effectiveness of ledipasvir/sofosbuvir (LDV/SOF) in treatment-experienced cirrhotic genotype 1 patients with chronic hepatitis C: a comparative analysis of Gilead sponsored trials with 4 real-world cohorts. J Hepatol 2016;64: S797.
5. Yakoot M, Abdo AM, Abdel-Rehim S, et al. Response tailored protocol versus the fixed 12 weeks course of dual sofosbuvir/daclatasvir treatment in Egyptian patients with chronic hepatitis C genotype-4 infection: a randomized, open-label, non-inferiority trial. EBioMedicine 2017;21: 182-7.
6. Hill AM, Tahat L, Mohammed MK, et al. Bioequivalent pharmacokinetics for generic and originator hepatitis C direct acting antivirals: ePoster at The AASLD-The Liver Meeting 2017, Abstract # 1078. Hepatology 2017;66:577A.
7. Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology 2017;66:371-8.
8. Wirth S, Rosenthal P, Gonzalez-Peralta RP, et al. Sofosbuvir and ribavirin in adolescents 12 to 17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology 2017;66:1102-10.
9. El-Sayed M, Hassany M, Asem N. A pilot study for safety and efficacy of 12 weeks sofosbuvir plus daclatasvir with or without ribavirin in Egyptian adolescents with chronic hepatitis C virus infection: Poster Presented at EASL-ILC 2017, Abstract # THU-412. J Hepatol 2017;66:S178.